InMed Pharmaceuticals shares surge 13.37% intraday after successful pharmacokinetic study of Alzheimer's candidate INM-901 in large animal models shows oral formulation with strong bioavailability and therapeutic potential for neurodegenerative diseases.

InMed Pharmaceuticals surged 13.37% intraday after successfully completing a pharmacokinetic study of its Alzheimer’s candidate INM-901 in large animal models, showing good oral bioavailability and therapeutic levels. The company is a clinical-stage biopharma firm focused on developing small molecule drugs for high unmet medical needs and commercializes rare cannabinoids via its BayMedica division.